Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia

Schizophrenia Research

Volumn 147, Issue 1, 2013, Pages 187-192

  Tay, Yi Hang ^a   Nurjono, Milawaty ^b   Lee, Jimmy ^b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF MENTAL HEALTH   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cardiovascular disease; Framingham risk score; Metabolic syndrome; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; WAIST CIRCUMFERENCE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; METABOLIC DISEASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SCHIZOPHRENIA;

EID: 84877131800     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.03.023     Document Type: Article

References (77)

1. Aguilar-Salinas C.A., Rojas R., Gomez-Perez F.J., Mehta R., Franco A., Olaiz G., Rull J.A. The metabolic syndrome: a concept hard to define. Arch. Med. Res. 2005, 36(3):223-231.
2. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998, 15(7):539-553.
3. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366(9491):1059-1062.
4. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 2006, 23(5):469-480.
5. Anderson K.M., Odell P.M., Wilson P.W., Kannel W.B. Cardiovascular disease risk profiles. Am. Heart J. 1991, 121(1 Pt 2):293-298.
6. Arango C., Bobes J., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr. Res. 2008, 104(1-3):1-12.
7. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002, 105(3):310-315.
8. Assunta M., Chapman S. "The world's most hostile environment": how the tobacco industry circumvented Singapore's advertising ban. Tob. Control 2004, 13(2):ii51-ii57.
9. Auquier P., Lancon C., Rouillon F., Lader M., Holmes C. Mortality in schizophrenia. Pharmacoepidemiol. Drug Saf. 2006, 15(12):873-879.
10. Barak Y., Swartz M., Plopsky I. Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients. Int. Clin. Psychopharmacol. 2005, 20(6):315-317.
11. Barnett A.H., Millar H.L., Loze J.Y., L'Italien G.J., van Baardewijk M., Knapp M. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259(4):239-247.
12. Barzi F., Patel A., Gu D., Sritara P., Lam T.H., Rodgers A., Woodward M. Cardiovascular risk prediction tools for populations in Asia. J. Epidemiol. Community Health 2007, 61(2):115-121.
13. Berger J.S., Jordan C.O., Lloyd-Jones D., Blumenthal R.S. Screening for cardiovascular risk in asymptomatic patients. J. Am. Coll. Cardiol. 2010, 55(12):1169-1177.
14. Bernardo M., Canas F., Banegas J.R., Casademont J., Riesgo Y., Varela C. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur. Psychiatry 2009, 24(7):431-441.
15. Blonde L., Kan H.J., Gutterman E.M., L'Italien G.J., Kim M.S., Hanssens L., McQuade R.D. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J. Clin. Psychiatry 2008, 69(5):741-748.
16. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr. Res. 2007, 90(1-3):162-173.
17. Bobes J., Arango C., Garcia-Garcia M., Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr. Res. 2010, 119(1-3):101-109.
18. Bresee L.C., Majumdar S.R., Patten S.B., Johnson J.A. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr. Res. 2010, 117(1):75-82.
19. Callaghan R.C., Boire M.D., Lazo R.G., McKenzie K., Cohn T. Schizophrenia and the incidence of cardiovascular morbidity: a population-based longitudinal study in Ontario, Canada. Schizophr. Res. 2009, 115(2-3):325-332.
20. Cameron A. The metabolic syndrome: validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction. Maturitas 2010, 65(2):117-121.
21. Chiu J.F., Bell A.D., Herman R.J., Hill M.D., Stewart J.A., Cohen E.A., Liau C.S., Steg P.G., Bhatt D.L. Cardiovascular risk profiles and outcomes of Chinese living inside and outside China. Eur. J. Cardiovasc. Prev. Rehabil. 2010, 17(6):668-675.
22. Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry 2004, 49(11):753-760.
23. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., De Bacquer D., Ducimetiere P., Jousilahti P., Keil U., Njolstad I., Oganov R.G., Thomsen T., Tunstall-Pedoe H., Tverdal A., Wedel H., Whincup P., Wilhelmsen L., Graham I.M. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 2003, 24(11):987-1003.
24. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J. Clin. Psychiatry 2006, 67(4):575-583.
25. Cuende J.I., Cuende N., Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur. Heart J. 2010, 31(19):2351-2358.
26. Curkendall S.M., Mo J., Glasser D.B., Rose Stang M., Jones J.K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J. Clin. Psychiatry 2004, 65(5):715-720.
27. D'Agostino R.B., Vasan R.S., Pencina M.J., Wolf P.A., Cobain M., Massaro J.M., Kannel W.B. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117(6):743-753.
28. Daumit G.L., Goff D.C., Meyer J.M., Davis V.G., Nasrallah H.A., McEvoy J.P., Rosenheck R., Davis S.M., Hsiao J.K., Stroup T.S., Lieberman J.A. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr. Res. 2008, 105(1-3):175-187.
29. de Leon J., Becona E., Gurpegui M., Gonzalez-Pinto A., Diaz F.J. The association between high nicotine dependence and severe mental illness may be consistent across countries. J. Clin. Psychiatry 2002, 63(9):812-816.
30. Del Valle M.C., Loebel A.D., Murray S., Yang R., Harrison D.J., Cuffel B.J. Change in Framingham risk score in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine. Prim. Care Companion J. Clin. Psychiatry 2006, 8(6):329-333.
31. D'Hoedt D., Bertrand D. Nicotinic acetylcholine receptors: an overview on drug discovery. Expert Opin. Ther. Targets 2009, 13(4):395-411.
32. Enger C., Weatherby L., Reynolds R.F., Glasser D.B., Walker A.M. Serious cardiovascular events and mortality among patients with schizophrenia. J. Nerv. Ment. Dis. 2004, 192(1):19-27.
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
34. First M.B., Spitzer Robert L., Gibbon Miriam, Williams Janet B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
35. Fontaine K.R., Heo M., Harrigan E.P., Shear C.L., Lakshminarayanan M., Casey D.E., Allison D.B. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001, 101(3):277-288.
36. Gautam S., Meena P.S. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J. Psychiatry 2011, 53(2):128-133.
37. Goff D.C., Cather C., Evins A.E., Henderson D.C., Freudenreich O., Copeland P.M., Bierer M., Duckworth K., Sacks F.M. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J. Clin. Psychiatry 2005, 66(2):183-194. (quiz 147, 273-184).
38. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agostino R.B., Stroup T.S., Davis S., Lieberman J.A. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 2005, 80(1):45-53.
39. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Circulation 2005, 112(17):2735-2752. (Epub 2005 Sep 12).
40. Hagg S., Lindblom Y., Mjorndal T., Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int. Clin. Psychopharmacol. 2006, 21(2):93-98.
41. Heng D., Ma S., Lee J.J., Tai B.C., Mak K.H., Hughes K., Chew S.K., Chia K.S., Tan C.E., Tai E.S. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006, 186(2):367-373.
42. Hennekens C.H., Hennekens A.R., Hollar D., Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 2005, 150(6):1115-1121.
43. Hippisley-Cox J., Coupland C., Robson J., Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ 2010, 9(341).
44. Hor K., Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J. Psychopharmacol. 2010, 24(4 Suppl.):81-90.
45. Hou Y.Z., Xiang Y.T., Yan F., Ungvari G.S., Dickerson F., Chiu H.F., Lai K.Y., Lee E.H., Li W.Y., Li W.X., Zhu Y.L., Dixon L.B. Cigarette smoking in community-dwelling patients with schizophrenia in China. J. Psychiatr. Res. 2011, 45(12):1551-1556.
46. Jackson R., Lawes C.M., Bennett D.A., Milne R.J., Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005, 365(9457):434-441.
47. Jin H., Folsom D., Sasaki A., Mudaliar S., Henry R., Torres M., Golshan S., Glorioso D.K., Jeste D. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr. Res. 2011, 125(2-3):295-299.
48. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
49. Laursen T.M., Munk-Olsen T., Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr. Opin. Psychiatry 2012, 25(2):83-88.
50. Lawrence D., Kisely S., Pais J. The epidemiology of excess mortality in people with mental illness. Can. J. Psychiatry 2010, 55(12):752-760.
51. Lee J., Heng D., Ma S., Chew S.K., Hughes K., Tai E.S. The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin. Endocrinol. 2008, 69(2):225-230.
52. Lee J., Nurjono M., Wong A., Salim A. Prevalence of metabolic syndrome among patients with schizophrenia in Singapore. Ann. Acad. Med. Singapore 2012, 41:457-462.
53. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., Drebing C., Berger R., Venn D., Sirota P., Zerbe G., Olincy A., Ross R.G., Adler L.E., Freedman R. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch. Gen. Psychiatry 2002, 59(12):1085-1096.
54. Lin C.C., Yu S.C., Wu B.J., Chang D.J. Measurement of waist circumference at different sites affects the detection of abdominal obesity and metabolic syndrome among psychiatric patients. Psychiatry Res. 2012, 197(3):322-326.
55. Liu J., Hong Y., D'Agostino R.B., Wu Z., Wang W., Sun J., Wilson P.W., Kannel W.B., Zhao D. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004, 291(21):2591-2599.
56. McCreadie R.G. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br. J. Psychiatry 2003, 183:534-539.
57. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80(1):19-32.
58. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand. 2009, 119(1):4-14.
59. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry 2007, 4:8-13.
60. Nurjono M., Lee J. Predictive utility of blood pressure, waist circumference and body mass index for metabolic syndrome in patients with schizophrenia in Singapore. Early Interv. Psychiatry 2012, 3(10):1751-7893.
61. Ratliff J.C., Palmese L.B., Reutenauer E.L., Srihari V.H., Tek C. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics 2012, 2:2.
62. Sarafidis P.A., Nilsson P.M. The metabolic syndrome: a glance at its history. J. Hypertens. 2006, 24(4):621-626.
63. Sicras-Mainar A., Rejas-Gutierrez J., Navarro-Artieda R., Blanca-Tamayo M. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. Eur. Psychiatry 2011, 30:30.
64. Smith S.C., Jackson R., Pearson T.A., Fuster V., Yusuf S., Faergeman O., Wood D.A., Alderman M., Horgan J., Home P., Hunn M., Grundy S.M. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation 2004, 109(25):3112-3121.
65. Soureti A., Hurling R., Murray P., van Mechelen W., Cobain M. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur. J. Cardiovasc. Prev. Rehabil. 2010, 17(5):519-523.
66. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16(2):434-444.
67. Tang Y.L., Gillespie C.F., Epstein M.P., Mao P.X., Jiang F., Chen Q., Cai Z.J., Mitchell P.B. Gender differences in 542 Chinese inpatients with schizophrenia. Schizophr. Res. 2007, 97(1-3):88-96.
68. Tolonen H., Mähönen M., Asplund K., Rastenyte D., Kuulasmaa K., Vanuzzo D., Tuomilehto J. Do trends in population levels of blood pressure and other cardiovascular risk factors explain trends in stroke event rates?: Comparisons of 15 populations in 9 countries within the WHO MONICA Stroke Project. Stroke 2002, 33(10):2367-2375.
69. Tsai K.-Y., Lee C.-C., Chou Y.-M., Su C.-Y., Chou F.H.-C. The incidence and relative risk of stroke in patients with schizophrenia: a five-year follow-up study. Schizophr. Res. 2012, 138(1):41-47.
70. Wilkin T. The metabolic syndrome, babies and bathwater. Diabetologia 2006, 49(2):421-422. (Feb, Epub 2005 Dec 28).
71. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
72. Wu Z., Yao C., Zhao D., Wu G., Wang W., Liu J., Zeng Z., Wu Y. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part I: morbidity and mortality monitoring. Circulation 2001, 103(3):462-468.
73. Wu Z., Yao C., Zhao D., Wu G., Wang W., Liu J., Zeng Z. Cardiovascular disease risk factor levels and their relations to CVD rates in China - results of Sino-MONICA project. Eur. J. Cardiovasc. Prev. Rehabil. 2004, 11(4):275-283.
74. Yazici M.K., Anil Yagcioglu A.E., Ertugrul A., Eni N., Karahan S., Karaagaoglu E., Tokgozoglu S.L. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261(1):69-78.
75. Zhang X.Y., Zhang R.L., Pan M., Chen da C., Xiu M.H., Kosten T.R. Sex difference in the prevalence of smoking in Chinese schizophrenia. J. Psychiatr. Res. 2010, 44(14):986-988.
76. Zhang X.Y., Chen da C., Xiu M.H., Haile C.N., Sun H., Lu L., Kosten T.A., Kosten T.R. Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study. PLoS One 2012, 7(5):3.
77. Zheng Y., Stein R., Kwan T., Yu C., Kwan J., Chen S.L., Hu D. Evolving cardiovascular disease prevalence, mortality, risk factors, and the metabolic syndrome in China. Clin. Cardiol. 2009, 32(9):491-497.